One possible explanation is that increased PD-L1 may not be sufficient to overcome the exaggerated pain caused by various algogenic substances released during advanced bone cancer, such as VEGF (41), TGF-β1 (10), and NGF (40). This evidence concerns the gene TGFB1 and bone neoplasm.